Successful use of recombinant activated factor VII in controlling upper gastrointestinal bleeding in a patient with relapsed acute myeloid leukemia

Related Experiment Video

Updated: Sep 23, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

R Hoffman, R Eliakim, T Zuckerman

    Journal of Thrombosis and Haemostasis : JTH
    |July 23, 2003
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
    08:31

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

    Published on: October 17, 2025

    Related Experiment Videos

    Last Updated: Sep 23, 2026

    Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
    08:13

    Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

    Published on: September 30, 2021

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
    08:31

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

    Published on: October 17, 2025

    Related Concept Videos

    Venous Thrombosis III: Interprofessional Care01:29

    Venous Thrombosis III: Interprofessional Care

    Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
    Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

    Anticoagulant Drugs: Low-Molecular-Weight Heparins

    Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

    Articles linked to this work by shared authors, journal, and citation graph.

    Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2024

    Treatments and clinical outcomes in stage II colon cancer patients with 12-gene Oncotype DX Colon Recurrence Score® assay-guided therapy: real-world data.

    ESMO open·2024

    Recommendations for the diagnosis and management of vaccine-induced immune thrombotic thrombocytopenia.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2021

    Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER).

    Annals of oncology : official journal of the European Society for Medical Oncology·2020

    Hypertrophic cardiomyopathy MYH7 mutation R723G alters mRNA secondary structure.

    Physiological genomics·2019

    Successful knock-in of Hypertrophic Cardiomyopathy-mutation R723G into the MYH7 gene mimics HCM pathology in pigs.

    Scientific reports·2018

    Enhanced Plasmin Generation Due to PAI-1 Deficiency Impairs Regulated Vascular Endothelial Cell Motility.

    Journal of thrombosis and haemostasis : JTH·2026

    Emicizumab Prophylaxis in People with Haemophilia A: Summary of Over 13 Years of Safety Data on Thromboembolic Events and Thrombotic Microangiopathy.

    Journal of thrombosis and haemostasis : JTH·2026

    SLFN14: An Elusive Regulator of Megakaryocytes and Platelets in Inherited Thrombocytopenia.

    Journal of thrombosis and haemostasis : JTH·2026

    The Quick and Owren prothrombin time assays: characteristics and performance in clinical routine.

    Journal of thrombosis and haemostasis : JTH·2026

    Combination of Thrombopoietin Receptor Agonists and Rituximab in Relapsed/Refractory Immune Thrombocytopenia: A Multicenter Real-World Study.

    Journal of thrombosis and haemostasis : JTH·2026

    JTH in Clinic: Venous Thromboembolism (VTE) Prophylaxis of Pediatric Patients at Risk of VTE.

    Journal of thrombosis and haemostasis : JTH·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us